MGI Tech Invites You to the 2025 CSGCT Conference: Showcasing Integrated Genomic Solutions and Advanced Sequencing Platforms

MGI Tech Co., Ltd.

Abbreviation: MGI

Booth No.: B02

MGI Tech Co., Ltd. (hereinafter referred to as “MGI”) adheres to the philosophy of “Innovative Intelligent Manufacturing Leading Life Sciences.” It focuses on the research and development of underlying technologies and product innovation for core tools centered around the “Read, Write, and Store” aspects of the central dogma of life sciences. MGI continuously provides users with comprehensive system solutions covering all scenarios and the full lifecycle in life science research and applications. Committed to leveraging genomics-centric multi-omics technologies to drive breakthroughs in scientific research and facilitate clinical translation, MGI collaborates with upstream and downstream partners in the life sciences and biotechnology industries to build an open, cooperative, and win-win industrial ecosystem.

MGI was founded in 2016. As of June 30, 2025, its business presence spans more than 110 countries and regions across six continents. The company has established nine R&D centers, seven production bases, and 13 customer experience centers worldwide, serving a cumulative total of over 3,560 users. As a provider of core tools for life sciences, MGI has not only achieved comprehensive strategic coverage of gene sequencing products across three technological pathways—“excited light,” “self-luminescence,” and “non-luminescence”—but is also the first company globally to possess both short-read and long-read sequencing products at large-scale commercial mass-production levels.

Product Introduction:

The DNBSEQ-G99 is currently one of the fastest mid-to-low throughput sequencers available worldwide. Built upon MGI’s core DNBSEQ™ sequencing technology, the G99 features optimized and enhanced core systems, including biochemistry, fluidics, optics, and temperature control. With an integrated computing module that enables seamless integration of sequencing and bioinformatics, it can complete PE150 sequencing within 12 hours. The instrument is suitable for a variety of applications, such as tumor targeted sequencing with small sample sizes, small-scale whole-genome sequencing (WGS), low-coverage WGS, individual identification, and 16S metagenomic sequencing, delivering high-efficiency, high-quality data output. Combined with the new generation of StandardMPS 2.0 sequencing reagents, it successfully elevates sequencing quality to Q40 (referring to sequencing quality for PE150 and shorter read lengths).

Pharmaceutical Applications:

Screening Validation, Microbial Risk Control and Traceability, Viral Safety Evaluation

Product Introduction:

The G100-ER is a nanopore gene sequencer featuring a dual-chip architecture that supports standalone operation and offers flexible throughput options. In addition to its superior performance characteristics—including ultra-long read lengths, real-time sequencing, and sustained continuous sequencing—the instrument effortlessly handles the challenges posed by complex sequences. It demonstrates excellent performance across a wide range of applications, such as amplicon sequencing, metagenomic sequencing, whole-genome sequencing of small genomes, low-coverage human whole-genome sequencing, and whole-transcriptome sequencing, highlighting its broad application potential.

Applications in Pharmaceuticals:

Screening Validation, Microbial Risk Control and Traceability, Viral Safety Evaluation

Product Introduction:

G400-ER is a nanopore gene sequencer equipped with high-throughput, high-density chips. It features long read lengths, high data output, and real-time sequencing capabilities, enabling efficient and accurate detection of complex genomes while simultaneously identifying base modifications. It is suitable for various applications, including whole-genome resequencing, genome assembly, full-length transcriptome sequencing, and epigenome sequencing.

Pharmaceutical Applications:

Screening Validation, Microbial Risk Control and Traceability, and Viral Safety Assessment

Product Introduction:

MGISP-Smart 8 is a professional-grade laboratory automated liquid handling robot, equipped with eight independent 1000 μL pipetting channels. The pipetting spacing and volume for each channel are independently controllable. It is compatible with various sample and reagent consumables, flexibly meeting diverse pipetting requirements. It is particularly suited for complex liquid handling tasks in experimental workflows such as low-to-medium throughput sequencing library preparation, positive clone picking, sample pooling, and plate coating, thereby comprehensively enhancing laboratory automation capabilities.

Applications in Pharmaceuticals:

Screening Validation, Microbial Risk Control and Traceability, Viral Safety Evaluation

To drive technological breakthroughs, industrial integration, policy alignment, and international cooperation in China’s cell and gene therapy (CGT) sector, and to propel the Chinese CGT industry to the forefront of global competition, the China Society for Gene and Cell Therapy (CSGCT) Conference was established.

Leveraging its close ties with the American Society of Gene & Cell Therapy (ASGCT), the 2025 CSGCT Annual Meeting will bring together leading scientists, clinical experts, multinational pharmaceutical companies, and overseas investment institutions from around the world. The event will showcase the most cutting-edge scientific advances, technologies, and applications in the global cell and gene therapy field, provide insights on market access, highlight high-quality collaborative projects, and facilitate matchmaking between overseas investors and investment opportunities. It aims to build a platform for in-depth exchange and cooperation between China’s cell and gene therapy industry and the global industrial chain.

The conference closely addressed the industry's hotspots, pain points, and bottlenecks, featuring1 Main Forum + 15 High-End Sub-Forums, covering the latest advancements in global gene therapy, immune cell therapy, in vivo CAR-T, adult stem cells and exosomes, iPSC-derived cell therapies, small nucleic acid drugs, gene editing, oncolytic viruses, tumor vaccines, as well as clinical applications and breakthroughs, CMC and testing, AI-driven drug R&D, registration and regulation, investment and financing, and BD matchmaking.Comprehensive Coverage of the Entire Industry Chain.

2025 2nd China Society for Gene and Cell Therapy (CSGCT) Congress

September 12–13, 2025

Zhongguancun National Independent Innovation Demonstration Zone Exhibition and Trading Center [Conference Center]

For more details, scan the QR code to visit the official conference website.